Portal-systemic shunting of blood is associated with hyperammonemia, an increased glutamine concentration in brain, an altered plasma neutral amino acid pattern, and high levels of several of the large neutral amino acids in brain. Since some of these amino acids are precursors for neurotransmitters and for other potentially neuroactive substances, high CNS levels of these amino acids may contribute to the development of encephalopathy. In order to determine the relative importance of changes in brain glutamine levels and changes in competition among the neutral amino acids for blood-brain transport, we measured the concentrations of the large neutral amino acids in plasma, cisternal cerebrospinal fluid and in brain tissue from various regions of dogs after end-to-side portacaval shunt. Although the changes in CSF amino acid levels correlated partially with altered amino acid plasma competitor ratios, better correlations were observed with the elevation of CSF glutamine. These results suggest a model of blood-brain amino acid transport in which a high level of glutamine in brain extracellular fluid competes with other neutral amino acids for efflux from brain, thus raising brain amino acid levels after portalsystemic shunting.
INTRODUCTION
One of the interesting problems in the study of hyperammonemia, liver failure and portal-systemic encephalopathy is the relationship of changes in the brain of the neurotransmitter-precursor amino acids to the development of encephalopathy. The amino acids of particular interest are tyrosine, phenylalanine and tryptophan, since they are involved in the synthesis in the brain of catecholamines, serotonin and of potential false transmitters such as octopamine or tryptamine7'5. These amino acids, together with leucine, isoleucine, valine, methionine, threonine and histidine, comprise the group of large neutral amino acids (LNAA) which share a common blood-brain transport system. In both humans and experimental animals with hepatic failure, many LNAA accumulate in the CNS to a greater extent than the changes in plasma concentrations of those amino acids would seem to predict18'11'15. The reason for this "excess" accumulation of LNAA in the CNS of patients or experimental animals with portal-systemic shunting and hyperammonemia has not been completely explained, although data have been presented which point to a role for elevated glutamine concentrations in the CNS in altering LNAA transport at the blood-brain barrier1 '12'13. In the following study in dogs, we compared the changes after portacaval anastomosis (PCA) in LNAA concentrations in plasma, cisternal CSF and in brain tissue. The latter was obtained only at sacrifice, but the plasma and CSF were sampled sequentially after PCA in order to follow changes over time. The results point to a significant role of elevated brain GLN as a competitor for efflux of the LNAA from the brain to the blood.
MATERIAL AND METHODS
Sixteen conditioned dogs weighing 9.5-23.9 kg were studied. Twelve dogs were anesthetized with sodium pentobarbital and subiected to an end-to-side portacaval shunt. The anastomosis was done with 5-0 Prolene sutures using the portal vein stump above the last splanchnic branch. After the operation 5% dextrose and saline solution were infused for 24 hours and penicillin and streptomycin were given. All dogs were allowed chow ad libitium. Weight, but not food intake, was monitored. The remaining four unoperated dogs served as controls.
From previous experience in this laboratory 24 The CSF concentration of GLN, presumably the product of cerebral ammonia detoxification with glutamic acid, rose after PCA to a much greater degree than in plasma. The increases in the concentration of PHE, TYR, HIS and TRP in CSF greatly exceeded the change either in absolute plasma levels or in the calculated competitor ratios. In all brain regions of dogs with PCA, the concentrations of GLN, TYR, PHE, TRP and HIS were several-fold higher than control, while MET and LEU were increased to a lesser extent. The regional concentrations of alanine (ALA) and of glutamic acid (GLU), the precursor for GLN synthesis, are also shown in Table 2 We tested whether the concentration of each of the LNAA in CSF was more closely correlated to the plasma competitor ratio of that amino acid or to the CSF concentration of GLU (Table 3) . For these correlations, 45 data-pairs were considered, significant correlations were observed between the CSF concentrations of THR, TYR, PHE and HIS and their respective plasma competitor ratios. Significant correlations were also found between the CSF concentration of GLN and that of MET, LEU, TYR, PHE and HIS. For all CSF amino acids except THR, the correlation with CSF GLN was better (higher value of the correlation coefficient (r) than with the plasma competitor ratio, suggesting that CSF LNAA concentrations are more strongly influenced by the CNS concentration of GLN than by the availability of LNAA for transport from the circulation. The relationship between CSF GLN and the four LNAA with the best correlations are shown graphically in Figure 1 . A similar comparisons of correlations was performed between the regional brain concentration of each LNAA and either the plasma competitor ratio or either concentration of GLN in that region (Table 4) . For these correlations, all 16 dogs were considered. As in the CSF, the best correlations were observed for MET, PHE, TYR and HIS. For MET and HIS, the better correlations were clearly with the brain GLN concentration; whereas, for PHE and TYR, their brain concentrations correlated about equally well both with the plasma competitor ratio and the brain GLN level.
The correlation between CSF GLN and regional GLN was tested in the twelve dogs with a PCS. The controls were omitted in this case since including them would have markedly improved all the correlations, statistically significant correlation was obtained only for cortex (r 0.645, p<0.05. Figure 2 ) and for cerebellum (r 0.593, p < 0.05). This result may reflect the fact that cerebral cortex and cerebellum constitute two of the largest brain regions in dogs and, hence, diffusion of amino acids from these regions may have considerable influence on the composition of CSF.
DISCUSSION
The lack of correlation in the present studies between encephalopathy grade and brain levels of amino acids, which are known or thought to be involved in synthesis Table   3 .
of true or false neurotransmitters, would seem to weaken the hypothesis that changes in brain amino acid levels are involved in encephalopathy. However, it should be noted that the design of the experiment may have resulted in significant bias if there was some difference in "sensitivity" to high brain LNAA levels in those dogs which exhibited encephalopathy at early or late times after the PCA. We have no evidence, however, that such differences in sensitivity exist.
Models of blood-brain amino acid transport consider the existence of at least three compartments: (a) blood or plasma, (b) brain extracellular fluid and the CSF, and (c) the intracellular fluid of brain cells22. Amino acids in a cerebral capillary must be transported across the two plasma membranes of the capillary endothelial cell in order to enter the extracellular fluid where they are then available to the transport systems of the brain cells themselves. Similarly, to exit from brain, amino acids must cross the brain cell membrane into the extracellular fluid and then must cross the two capillary membranes in order to reach the circulation. The total In the present studies, with the exception of THR, the magnitude of the increase or decrease in absolute plasma LNAA levels was not the same as the changes in concentration of amino acids in CSF or in brain. The magnitude of change in the calculated plasma competitor ratios for each LNAA was also considerably less than the change in CSF or brain LNAA after PCA. These observations strongly suggest that some factor other than the change in plasma LNAA concentrations was responsible for the rise in CSF and brain LNAA levels after PCA.
Elevated concentrations of GLN in lumbar CSF are commonly found in patients with encephalopathy resulting from liver disease9. The synthesis in brain of GLN from ammonia and glutamic acid apparently occurs very rapidly and primarily in glial astrocytes, where the enzyme glutamine synthetase is located16. The elevated CSF GLN concentration in patients almost certainly reflects accelerated detoxification of ammonia in brain secondary to hyperammonemia14. In the present studies, the CSF GLN concentration rose from levels which were less than those in plasma preoperatively to levels which were markedly greater than in plasma (Table 1) . This change in the CSF/plasma GLN ratio is strong evidence that transport of GLN from extracellular fluid to blood across the capillary barrier was slow compared to the rate of GLN synthesis, at least until CSF GLN reached a much higher level. Presumably, at the higher level, synthesis of GLN was matched by the rate of removal of GLN from the ECF. The present studies suggest that competition for transport from ECF to blood among GLN and the other LNAA can be an important determinant of brain LNAA levels in liver disease. The increased CSF concentration of several of the LNAA was better correlated with the increased CSF GLN concentration than with the change in the plasma competitor ratios of those amino acids (Table 3) . This does not imply that competition among plasma neutral amino acids for transport across the blood-brain barrier is not an important determinant of brain amino acid levels. On the contrary, Smith, et al. 24 showed that infusing a solution rich in the BCAA could drastically reduce the CSF levels of the other LNAA in dogs with portal-systemic encephalopathy. The lower degree of correlation between plasma competitor ratios and CSF LNAA levels suggests that, under the pathological conditions of the present study, the GLN concentration in the CNS was a more important determinant of the concentrations of the LNAA in the brain or CSF. 
